Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013 (mitazalimab)
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • ATOR-1144
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors and collaborators
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV

  • Alligator Bioscience - Innovating Tumor-Directed Immunotherapy

  • Cancer cure is our passion - research is our foundation

  • Tumor-directed immunotherapies for major unmet medical needs within cancer

  1. 1
  2. 2
  3. 3

Latest News

  • 1 Apr 2020 – Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic
  • 31 Mar 2020 – Notice of annual general meeting in Alligator Bioscience AB (publ)
  • 5 Mar 2020 – Alligator Bioscience appoints Andreas Johannesson as interim Chief Financial Officer
  • 2 Mar 2020 – Alligator Bioscience’s Annual Report 2019 published
More news

Calendar

  • 23 Apr 2020 ‐ Interim report January-March 2020
  • 13 Jul 2020 ‐ Interim report April-June 2020

Annual Report 2019

Read Alligator Bioscience's Annual Report 2019 here.

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree